コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 fety of markedly lowering LDL-C (low-density lipoprotein cholesterol).
2 ned by the log of (triglyceride/high-density lipoprotein cholesterol).
3 5% CI, 1.01-1.48) independent of low-density lipoprotein cholesterol.
4 vascular disease irrespective of low-density lipoprotein cholesterol.
5 us, systolic blood pressure, and low-density lipoprotein cholesterol.
6 medium LDL particles, and total/high-density lipoprotein cholesterol.
7 rsely associated with serum non-high-density lipoprotein cholesterol.
8 cholesterol, triglycerides, or high-density lipoprotein cholesterol.
9 th hypertriglyceridemia and low high-density lipoprotein cholesterol.
10 es potent statin therapy and low low-density lipoprotein cholesterol.
11 to hypertriglyceridemia and low high-density lipoprotein cholesterol.
12 ially improve triglycerides and high-density lipoprotein cholesterol.
13 ressure, total cholesterol, and high-density lipoprotein cholesterol.
14 ssure, albuminuria, smoking, and low-density lipoprotein cholesterol.
15 ion near APOC1P1 associated with low-density lipoprotein cholesterol.
16 in, systolic blood pressure, and low-density lipoprotein cholesterol.
17 al, HR-corrected QT interval or high-density lipoprotein-cholesterol.
18 inverse association of FT4 with low-density lipoprotein-cholesterol.
19 rograms on agents to raise HDL (high-density lipoprotein) cholesterol.
20 not significantly different for low-density lipoprotein cholesterol (0.04 mg/dL; 95% CI, -0.01 to 0.
21 tin nonusers (n = 71), elevated high-density lipoprotein cholesterol (+0.08 mmol/L; P = 0.03), high-d
22 mg/dL; 95% CI, -0.01 to 0.10), high-density lipoprotein cholesterol (-0.01 mg/dL; 95% CI, -0.03 to 0
23 [1.1-2.1]), and borderline low high-density lipoprotein cholesterol (1.4 [1.0-1.8]) remained signifi
24 holesterol (1.6 [1.2-2.2]), high low-density lipoprotein cholesterol (1.6 [1.1-2.1]), and borderline
25 (3.7 [2.0-7.0]), borderline high low-density lipoprotein cholesterol (1.6 [1.2-2.2]), high low-densit
26 holesterol (27.9 to 60.0%), non-high-density lipoprotein cholesterol (10.0 to 36.6%), apolipoprotein
27 ere observed at week 12 for non-high-density lipoprotein cholesterol (-10.8% vs 2.3%; difference, -13
28 s. 17%, respectively) and higher low-density lipoprotein cholesterol (117 vs. 107 vs. 103 mg/dl, resp
29 67 [95% CI, 2.38-2.95]), or low high-density lipoprotein cholesterol (2.63 [95% CI, 2.33-2.94]), but
30 cholesterol (1.3 to 32.9%), very-low-density lipoprotein cholesterol (27.9 to 60.0%), non-high-densit
31 ter acute coronary syndrome with low-density lipoprotein cholesterol 50 to 125 mg/dL were randomized
32 (a) is associated with increased low-density lipoprotein cholesterol, a family history of cardiovascu
34 isoleucine and lower levels of high-density lipoprotein cholesterol, acetate, and apolipoprotein A1
35 /kexin type 9), markedly reduces low-density lipoprotein cholesterol across diverse patient populatio
36 4 g/d prescription n-3 FA, non-high-density lipoprotein cholesterol and apolipoprotein B were modest
37 9) inhibitor evolocumab reduced low-density lipoprotein cholesterol and cardiovascular events in the
38 ificant variants associated with low-density lipoprotein cholesterol and coronary heart disease at AP
40 of these foods with plasma non-high-density lipoprotein cholesterol and for red and processed meat w
41 ng for biomarkers, particularly high-density lipoprotein cholesterol and glycated hemoglobin, led to
42 inment, exercise, levels of non-high-density lipoprotein cholesterol and high-sensitivity C-reactive
43 was positively associated with high-density-lipoprotein cholesterol and intakes of polyunsaturated f
44 P = 0.002), and third-trimester high-density lipoprotein cholesterol and low-density lipoprotein chol
45 etic exposure to lower levels of low-density lipoprotein cholesterol and lower systolic blood pressur
46 The concentrations of high- and low-density-lipoprotein cholesterol and triglycerides are influenced
47 Reductions from baseline in LDL (low-density lipoprotein) cholesterol and Lp(a) (lipoprotein [a])were
48 aminotransferases, elevation of (low-density lipoprotein) cholesterol and steatosis in hepatocytes.
49 n that therapies that lower LDL (low-density lipoprotein)-cholesterol and triglycerides reduce corona
50 ers (B) (NT-proBNP, hs-cTnT, and low-density lipoprotein cholesterol), and clinical variables (C) (sm
53 blood pressure, smoking status, high-density lipoprotein cholesterol, and hemoglobin A(1c) were simil
54 e atherogenesis independently of low-density lipoprotein cholesterol, and high sensitivity C-reactive
55 ties (high fasting glucose, low high-density lipoprotein cholesterol, and high triglyceride levels an
56 ed for traditional risk factors, low-density lipoprotein cholesterol, and high-sensitivity C-reactive
57 her blood HDL cholesterol, lower low-density lipoprotein cholesterol, and lower risk of coronary hear
58 sm, educational attainment, and high-density lipoprotein cholesterol, and significant negative geneti
59 nic lipid levels, including non-high-density lipoprotein cholesterol, apolipoprotein B, and lipoprote
60 al, low-density lipoprotein, or high-density lipoprotein cholesterol, apolipoproteins A1 and B, or bl
61 us, systolic blood pressure, and low-density lipoprotein cholesterol appear to be the most important
62 tive exposure to lower levels of low-density lipoprotein cholesterol are not associated with neurocog
63 ntion to percentage reduction in low-density lipoprotein cholesterol as a treatment goal and to long-
64 research has established LDL-C (low-density lipoprotein cholesterol) as a causal factor in the devel
65 The percent change in Lp(a) and low-density lipoprotein cholesterol at 48 weeks in patients taking e
66 tate aminotransferase, total and low-density lipoprotein cholesterol at baseline (<0.05), and over fo
67 de significantly associated with low-density lipoprotein cholesterol based on 3203 subjects and that
68 acebo in individuals with normal low-density lipoprotein cholesterol but increased C-reactive protein
69 inhibitors substantially reduce low-density lipoprotein cholesterol, but it is presently unclear whe
70 iduals to <130 mm Hg or lowering low-density lipoprotein cholesterol by 30% would be expected to lowe
72 wer median time-weighted average low-density lipoprotein cholesterol compared with placebo/simvastati
73 ively associated with serum non-high-density lipoprotein cholesterol concentration and systolic blood
74 body mass index, triglycerides, high-density lipoprotein cholesterol concentrations, and type 2 diabe
75 , including variants involved in low-density lipoprotein cholesterol concentrations, schizophrenia, a
77 Pericardial fat volumes and LDL (low-density lipoprotein) cholesterol concentrations correlated inver
78 scular disease (CVD) context and low density lipoprotein-cholesterol concentrations within a saturate
79 clinical covariates (including high-density lipoprotein cholesterol content, coronary artery disease
80 scores for BMI, HDL cholesterol, low-density lipoprotein cholesterol, coronary artery disease, C-reac
81 0.010] per year), mean levels of low-density lipoprotein cholesterol declined from 92 mg/dL (95% CI,
82 ferential responses in total and low-density lipoprotein cholesterol (decreased in LFHC group only),
83 iants associated with increased high-density lipoprotein-cholesterol, decreased triglyceride levels,
84 ood pressure and ratio of total-high-density lipoprotein cholesterol), family history of premature CV
85 ged 12-19 years), mean levels of low-density lipoprotein cholesterol, geometric mean levels of trigly
86 factors (pulse pressure, total/high density lipoprotein cholesterol, glycosylated hemoglobin), diabe
87 f meeting trial goals for LDL-C (low-density lipoprotein cholesterol, goal <70 mg/dL) or systolic blo
88 s: targeting of statin dose (not low-density lipoprotein cholesterol goals), additional tests for ris
91 with HeFH (age, 6-<18 years) and low-density lipoprotein cholesterol >4.9 mmol/L or >4.1 mmol/L in co
92 edian baseline of 216 mg/dl) and low-density lipoprotein cholesterol >40 and <=100 mg/dl (median base
93 cerides >=135 and <500 mg/dL and low-density lipoprotein cholesterol >40 and <=100 mg/dL and a histor
94 cerides >150 but <=450 mg/dL and low-density lipoprotein cholesterol >=100 mg/dL (n=83 for single asc
95 n cholesterol >=70 mg/dL or non-high-density lipoprotein cholesterol >=100 mg/dL despite maximum tole
96 terol (LDL-C) >=70 mg/dl or non-high-density lipoprotein cholesterol >=100 mg/dl to evolocumab or pla
97 diabetes mellitus, hypertension, low-density lipoprotein cholesterol >=100 mg/dl, and smoking; multip
98 l (LDL-C) level >=70 mg/dl, non-high-density lipoprotein cholesterol >=100 mg/dl, or apolipoprotein B
99 dary prevention in patients with low-density lipoprotein cholesterol >=70 mg/dL or non-high-density l
101 pecific for triglycerides (TG), high density lipoprotein cholesterol (HDL), low density lipoprotein c
103 ith CVD risk factors, including high-density lipoprotein cholesterol (HDL-C) (beta 0.40, 95% confiden
104 [0.11 mmol/l]; p < 0.001), non-high-density lipoprotein cholesterol (HDL-C) (HR: 1.05; 95% CI: 1.01
105 ipoprotein cholesterol (LDL-c), high density lipoprotein cholesterol (HDL-c) and triglycerides (TG) f
107 L will lead to sustained plasma high-density lipoprotein cholesterol (HDL-C) increase and, potentiall
108 emic stroke, and a low level of high-density lipoprotein cholesterol (HDL-C) is also considered to be
109 age, age at initiation, and non-high-density lipoprotein cholesterol (HDL-C) level on the expected ra
110 study asks if elevating plasma high density lipoprotein cholesterol (HDL-C) levels by inhibition of
112 protein cholesterol (LDL-C) and high-density lipoprotein cholesterol (HDL-C) were either directly mea
113 diastolic blood pressure (DBP), high-density-lipoprotein cholesterol (HDL-C), and glycated haemoglobi
114 e (TG), total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipopro
115 ipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG)
117 cluding total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
118 instruments for blood levels of high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein
121 sociated with triglycerides and high-density lipoprotein cholesterol (HDL-C; cg27243685; P=8.1E-26 an
122 cholesterol (LDL-cholesterol), high-density lipoprotein cholesterol (HDL-cholesterol), total cholest
123 fractions (triglycerides [TGs], high-density lipoprotein cholesterol [HDL-C], low-density lipoprotein
124 lipoprotein cholesterol (LDLc), high-density lipoprotein cholesterol (HDLc) and triglycerides (TG)].
125 significantly higher levels of high density lipoprotein cholesterol (HDLc) were observed in individu
126 te blood cell count, vitamin D, high-density lipoprotein cholesterol), healthier lifestyles (physical
127 lays an essential role in LDL-C (low-density lipoprotein cholesterol) homeostasis through regulating
128 hite blood cell count and lower high-density lipoprotein cholesterol in men, and with higher BMI and
129 e of lower levels of circulating low-density lipoprotein cholesterol in mice lacking miR-146a in BM-d
130 , whereas EPA-only did not raise low-density lipoprotein cholesterol in very high triglycerides.
132 reased in LFHC group only), and high-density lipoprotein cholesterol (increased in VHFLC group only).
133 lso found evidence that elevated low-desnity lipoprotein cholesterol is a causal risk factor for ALS.
135 y lipoprotein cholesterol (HDL), low density lipoprotein cholesterol (LDL), or total cholesterol (TC)
136 ients with primary elevations of low-density lipoprotein cholesterol (LDL-C) >/=190 mg/dL are at a hi
137 ally evident atherosclerosis and low-density lipoprotein cholesterol (LDL-C) >=70 mg/dl or non-high-d
138 l, total cholesterol <240 mg/dl, low-density lipoprotein cholesterol (LDL-C) <160 mg/dl, and high-den
139 intervention (PCI) with baseline low-density lipoprotein cholesterol (LDL-C) <=70 mg/dl are scarce.
140 .42) but resulted in higher mean low-density lipoprotein cholesterol (LDL-c) (2.86 vs 2.60 mmol/L; ad
141 rates of statin utilization and low-density lipoprotein cholesterol (LDL-C) achieved 1-year post MI.
142 tions of total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C) and apolipoprotein B (ap
143 ecretion were increased, and the low-density lipoprotein cholesterol (LDL-C) and blood urea nitrogen
145 which causes elevated levels of low-density lipoprotein cholesterol (LDL-C) and increased risk of pr
146 onship between exposure to lower low-density lipoprotein cholesterol (LDL-C) and lower systolic blood
148 on, and subsequently circulating low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG) l
151 s of total serum cholesterol and low-density lipoprotein cholesterol (LDL-C) at 6 months or more of f
152 ndly titrated to target achieved low-density lipoprotein cholesterol (LDL-C) between 25 and 50 mg/dL.
153 persistently lowered mean +/- SE low-density lipoprotein cholesterol (LDL-C) by 56% +/- 0.6% (n = 1,0
154 (CVD) increases with increasing low-density lipoprotein cholesterol (LDL-C) concentration and exposu
155 howed the benefit of targeting a low-density lipoprotein cholesterol (LDL-C) concentration of <70 mg/
160 viduals with increased levels of low-density lipoprotein cholesterol (LDL-C) have shown modest result
163 statin therapy, with a baseline low-density lipoprotein cholesterol (LDL-C) level >=70 mg/dl, non-hi
164 achieve sufficient reduction in low-density lipoprotein cholesterol (LDL-C) level with available lip
166 rotic cardiovascular disease and low-density lipoprotein cholesterol (LDL-C) levels >=70 mg/dl or non
167 ibody against PCSK9 that reduces low-density lipoprotein cholesterol (LDL-C) levels by 55% to 75%.
168 ients with persistently elevated low-density lipoprotein cholesterol (LDL-C) levels despite use of st
169 protein (CETP) inhibitors lower low-density lipoprotein cholesterol (LDL-C) levels without reducing
173 the effects of lifetime reduced low-density lipoprotein cholesterol (LDL-C) on cardiovascular events
174 .26 mmol/l]; p < 0.001), but not low-density lipoprotein cholesterol (LDL-C) or HDL-C, were associate
175 ver, the presence of an elevated low-density lipoprotein cholesterol (LDL-C) polygenic risk score fur
176 study, higher baseline levels of low-density lipoprotein cholesterol (LDL-C) predicted greater benefi
178 acute coronary syndromes (ACS), low-density lipoprotein cholesterol (LDL-C) target levels are freque
179 monoclonal antibodies can reduce low-density lipoprotein cholesterol (LDL-C) to very low levels when
180 re weighted by associations with low-density lipoprotein cholesterol (LDL-C) using data from lipid ge
181 protein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured by using M
183 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides (TG).
184 lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and triglycerides, for
185 l antibody that robustly reduces low-density lipoprotein cholesterol (LDL-C), for the treatment of AL
186 l risk factors for CAD including low density lipoprotein cholesterol (LDL-c), high density lipoprotei
187 nancy losses; total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotei
188 evated cholesterol, particularly low-density lipoprotein cholesterol (LDL-C), is frequently seen in o
189 erogenic lipoproteins, including low-density lipoprotein cholesterol (LDL-C), reduces the risk of isc
190 weaker on women than on men, for low-density lipoprotein cholesterol (LDL-C), uric acid (UA) and diab
194 to a greater extent than they do low-density lipoprotein cholesterol (LDL-C): fibrates, niacin, and m
195 change (baseline to week 24) in low-density lipoprotein cholesterol (LDL-C); secondary endpoints inc
197 c load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-in
198 ased ABCA1 expression, increased low-density lipoprotein-cholesterol (LDL-C) and cholesterol blood le
199 e was a significant reduction in low density lipoprotein-cholesterol (LDL-C), an increase in CEC and
200 ls of total cholesterol (T-CHL), low density lipoprotein-cholesterol (LDL-CHL), and resistin were hig
201 non-HDL-C, direct and calculated low-density lipoprotein cholesterol [LDL-C], and apolipoproteins [Ap
202 lipoprotein cholesterol [HDL-C], low-density lipoprotein cholesterol [LDL-C], total cholesterol [TC])
204 hout ezetimibe and reductions in low-density lipoprotein cholesterol (LDLc) and C-reactive protein (C
205 ype was associated with elevated low density lipoprotein cholesterol (LDLc) and total cholesterol (TC
206 profile [total cholesterol (TC), low-density lipoprotein cholesterol (LDLc), high-density lipoprotein
207 tolic blood pressure <120 mm Hg, low-density lipoprotein cholesterol level <2.0 mmol/L [<77.3 mg/dL],
208 -0.16]; 23 trials [n = 58022]), low-density lipoprotein cholesterol level (-2.58 mg/dL [95% CI, -4.3
209 de level (-40%, -29%, and -8%), high-density lipoprotein cholesterol level (32%, 30%, and 7%), use of
210 d triglyceride levels and lower high-density lipoprotein cholesterol level are causal risk factors fo
213 ive lipid-lowering therapy (to a low-density lipoprotein cholesterol level of <70 mg/dl) halts plaque
214 a recent first MI and a baseline low-density lipoprotein cholesterol level of 1.81 mmol/L (70 mg/dL)
215 52 to 5.63 mmol per liter) and a low-density lipoprotein cholesterol level of 41 to 100 mg per decili
216 mg/dL or a final screening non-high-density lipoprotein cholesterol level of at least 100 mg/dL.
219 ion) in the cohort with elevated low-density lipoprotein cholesterol levels (ie, >/=190 mg/dL), 52.4%
220 kexin type 9 inhibitors) reduce low-density lipoprotein cholesterol levels and cardiovascular event
221 reductions in blood pressure and low-density lipoprotein cholesterol levels and improvements in measu
222 was no relation between baseline low-density lipoprotein cholesterol levels and magnitude of VTE risk
223 l, high-density lipoprotein, and low-density lipoprotein cholesterol levels compared with patients in
224 otic cardiovascular disease with low-density lipoprotein cholesterol levels of at least 70 mg/dL (to
225 price of $10311 in patients with low-density lipoprotein cholesterol levels of at least 80 mg/dL.
226 third-trimester, the effect of high-density lipoprotein cholesterol levels on the risk for small-for
227 sity lipoprotein cholesterol and low-density lipoprotein cholesterol levels were associated with an i
228 days, type 2 diabetes, and low high-density lipoprotein cholesterol levels were eligible for enrollm
230 uous measures of blood pressure, low-density lipoprotein cholesterol levels, fasting glucose levels,
231 evated triglyceride levels, low high-density lipoprotein cholesterol levels, high blood pressure, and
232 nal risk factors for CVD include low-density lipoprotein cholesterol levels, hypertension, renal dise
233 ow-density lipoprotein, and non-high-density lipoprotein cholesterol levels, in triglyceride levels,
234 drome, type 2 diabetes, and low high-density lipoprotein cholesterol levels, the selective bromodomai
238 morbidities and their treatment, low-density lipoprotein cholesterol, liver biochemistries, and lengt
239 lood pressure, fasting glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholest
240 of PTV at CETP displayed higher high-density lipoprotein cholesterol, lower low-density lipoprotein c
241 y lipoprotein cholesterol, lower low-density lipoprotein cholesterol, lower triglycerides, and lower
243 c blood pressure <140 mm Hg, and low-density lipoprotein cholesterol <2.5 mmol/L were associated with
244 ters-aspirin use, lipid control (low-density lipoprotein cholesterol <70 mg/dL or statin therapy), bl
246 in dietary cholesterol intake and changes in lipoprotein-cholesterol markers for cardiovascular disea
247 7.31%, -12.57%; p < 0.001), non-high-density lipoprotein cholesterol (MD -18.17%; 95% CI -21.14%, -15
248 CI -21.14%, -15.19%; p < 0.001), low-density lipoprotein cholesterol (MD -22.94%; 95% CI -26.63%, -19
249 I -17.41%, -12.95%; p < 0.001), high-density lipoprotein cholesterol (MD -5.83%; 95% CI -6.14%, -5.52
251 Extended elevations of non-high-density lipoprotein cholesterol (non-HDL-C) across a lifespan ar
252 ein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) were significantly d
253 ibutable fractions for SBP, non-high-density lipoprotein cholesterol (non-HDL-C), diabetes mellitus,
254 1 year: systolic blood pressure, low-density lipoprotein cholesterol, nonsmoking, physical activity,
256 mass, high blood pressure, low high-density-lipoprotein cholesterol or high triglycerides, and high
257 scavenger receptors for oxidized low-density lipoprotein cholesterol (ox-LDL), plays a crucial role i
258 able analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and h
260 ained by lowering of non-HDL-C (high-density lipoprotein cholesterol), rather than increases in HDL-C
261 n use, and total cholesterol to high-density lipoprotein cholesterol ratio were associated with CVEs.
262 95% CI, 1.30-2.76) for total to high-density lipoprotein cholesterol ratio, 2.59 (95% CI, 1.76-3.83)
263 determine whether the total to high-density lipoprotein cholesterol ratio, high-sensitivity cardiac
264 itiation of statin treatment for low-density lipoprotein cholesterol reduction in children with HeFH.
265 on quantitative trait loci for a low-density lipoprotein cholesterol-related differentially methylate
266 schooling (rG=0.18, s.e.=0.03), high-density lipoprotein cholesterol (rG=0.28, s.e.=0.05), smoking (r
267 lesterol (TRL-C) and small-dense low-density lipoprotein cholesterol (sdLDL-C) concentrations associa
268 duction and improved small dense low-density lipoprotein-cholesterol (sdLDL-C) profiles, QoL and URTI
270 density lipoprotein cholesterol, low-density lipoprotein cholesterol, systolic blood pressure, total
271 w-density lipoprotein (LDL) and high-density lipoprotein cholesterols, systolic and diastolic BP star
272 ion, hemoglobin A1c testing, and low-density lipoprotein cholesterol testing), prescribing appropriat
273 in, systolic blood pressure, and low-density lipoprotein cholesterol than contemporary guideline targ
274 f triglyceride and low- and very-low-density lipoprotein cholesterol than controls, suggesting impair
275 its estimated from reductions in low-density lipoprotein cholesterol that occurred in PCSK9i trials w
276 Low-fat diets tend to improve low-density lipoprotein cholesterol the most, while lower-carbohydra
277 g that therapeutic modulation of low-density lipoprotein cholesterol, the lipoprotein lipase pathway
278 pient mice all had low levels of low-density lipoprotein cholesterol to promote plaque regression.
279 dence to support lowering LDL-c (low-density lipoprotein cholesterol) to reduce cardiovascular morbid
281 ected to agents that reduce LDL (low-density lipoprotein) cholesterol, triglyceride, and Lp[a] (lipop
282 of SCOPA to two GWAS of high-and low-density lipoprotein cholesterol, triglycerides and body mass ind
283 levels of apolipoprotein B, very-low-density lipoprotein cholesterol, triglycerides, diglycerides, to
284 lood sample (total cholesterol, high-density lipoprotein cholesterol, triglycerides, glucose, fasting
285 plasma glucose, glycohemoglobin, low-density lipoprotein cholesterol, triglycerides, high-sensitivity
286 s (either low or high) of plasma low-density lipoprotein cholesterol, triglycerides, or high-density
287 ith changes of fasting glucose, high-density lipoprotein-cholesterol, triglycerides, systolic blood p
288 t circumference; total, high and low density lipoprotein cholesterol; triglycerides; glucose; systoli
289 pectively evaluate whether triglyceride-rich lipoprotein cholesterol (TRL-C) and small-dense low-dens
290 ve biomarkers (concentration of high-density lipoprotein cholesterol, vitamin D and C-reactive protei
291 R per 1-mmol/L reduction in non-high-density lipoprotein cholesterol was 0.79 (95% CI, 0.76-0.82; P<0
293 ohemoglobin difference), whereas low-density lipoprotein cholesterol was associated with 35% to 50% g
295 05-1.26), while a high level of high-density lipoprotein cholesterol was protective (aOR, 0.45; 95% C
296 ntervention, and higher level of low-density lipoprotein cholesterol were independent predictors of e
297 asma triglycerides and high- and low-density lipoprotein cholesterol were measured in 34 153 individu
298 as small + medium LDL and total/high-density lipoprotein cholesterol were unaffected by protein sourc
299 ide lowering and do not increase low-density lipoprotein cholesterol when used as monotherapy or in c
300 30% with concurrent increases in low-density lipoprotein cholesterol, whereas EPA-only did not raise